Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 46
Filter
1.
J Heart Valve Dis ; 23(6): 721-6, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25790619

ABSTRACT

BACKGROUND AND AIM OF THE STUDY: Mitral regurgitation (MR) is a common disorder for which mitral valve surgery is an established therapy. Although surgical indications are clearly defined for the management of valvular heart disease, a gap exists between current guidelines and their effective application. The study aim was to provide an insight into the diagnostic information provided for cardiac surgeons before performing mitral valve surgery. METHODS: The source documents and echocardiographic studies of 100 patients, referred by nine hospitals, were screened for arguments for MR severity justifying referral for surgery. Details of the documented MR mechanism, mitral annulus (MA) size, tricuspid regurgitation (TR) severity and annulus size were also noted. RESULTS: According to the referring physician, MR was severe in 83% and moderate-to-severe in 17%. In the great majority of patients (98%) the MR mechanism was mentioned, although specific information on the prolapsing scallops was available in only 17% of cases. The recommended primary determinants of MR severity, vena contracta and proximal isovelocity surface area (PISA) were measured in only 22% and 31% of patients, respectively. In 94% of patients with available PISA information this was described only qualitatively. Correct image expansion using the zoom mode was performed in only 25% of these patients, and a correct adaptation of the Nyquist limit in only 6%. Tricuspid annulus measurements guiding the need for concomitant tricuspid valvuloplasty in patients with less than severe TR were reported in only 6% of patients. CONCLUSION: These data demonstrate a clear and important gap between current guidelines and real-world practice with regards to the echocardiographic diagnostic information provided to the surgeon before performing mitral valve surgery.


Subject(s)
Cardiac Surgical Procedures/methods , Guideline Adherence , Mitral Valve Insufficiency , Tricuspid Valve Insufficiency , Aged , Echocardiography, Transesophageal/methods , Echocardiography, Transesophageal/statistics & numerical data , Female , Humans , Male , Middle Aged , Mitral Valve/diagnostic imaging , Mitral Valve/surgery , Mitral Valve Insufficiency/diagnosis , Mitral Valve Insufficiency/surgery , Needs Assessment , Netherlands , Patient Selection , Practice Guidelines as Topic , Referral and Consultation , Severity of Illness Index , Tricuspid Valve/diagnostic imaging , Tricuspid Valve/surgery , Tricuspid Valve Insufficiency/diagnosis , Tricuspid Valve Insufficiency/surgery
2.
J Virol Methods ; 194(1-2): 113-7, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23978605

ABSTRACT

The novel SPF10 real-time PCR assay allows the simultaneous amplification and detection of the HPV target. That way, LiPA analysis of the HPV-negative samples can be avoided, reducing workload and cost. This study aims to evaluate the performance of the SPF10 real-time PCR in combination with the LiPA assay for HPV detection and typing in cervical samples. Thirty-nine cervical samples were subjected to the SPF10 conventional PCR in combination with the LiPA assay. Subsequently, the SPF10 real-time PCR was performed to enable the comparison between the SPF10 conventional and the real-time PCR results. In case of discrepancy, the samples were subjected to the CLART HPV2 assay. As a result, 27 out of 39 samples were identified as HPV-positive by the SPF10 real-time PCR and were genotyped further by the LiPA assay. Twenty samples (74.1%) showed an absolute agreement between the conventional and real-time SPF10 PCR (concordant), three (11.1%) displayed additional or fewer types (compatible), two (7.4%) did not show any similarity between both assays (discordant) and the remaining two (7.4%) were LiPA-negative. The two assays showed an excellent strength of agreement for individual (κ=0.932) and multiple genotype detection (κ=0.834). In conclusion, the two SPF10 PCR methods are comparable. Therefore, the SPF10 real-time PCR with subsequent LiPA could be used for the detection and genotyping of HPV in cervical samples.


Subject(s)
Cervix Uteri/virology , Molecular Diagnostic Techniques/methods , Papillomaviridae/classification , Papillomaviridae/isolation & purification , Papillomavirus Infections/diagnosis , Papillomavirus Infections/virology , Real-Time Polymerase Chain Reaction/methods , Female , Humans , Papillomaviridae/genetics
3.
J Virol Methods ; 187(1): 166-71, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23018060

ABSTRACT

The SPF10 PCR targets a conserved 65bp region of the HPV L1 gene for broad-spectrum amplification. The LiPA assay allows subsequent genotyping of the HPV amplicons. This study aims to develop a SPF10 real-time PCR to achieve simultaneous amplification and detection of the HPV target. That way, LiPA analysis of the HPV-negative samples can be avoided, reducing workload and cost. The real-time PCR shows an analytical sensitivity of 29.7 copies for HPV 6, 16, 18 and 31 and an HPV-specific melting peak. Thirty-one HPV DNA plasmids were genotyped correctly using the SPF10 real-time PCR in combination with the LiPA. Here, the LiPA assay was performed at an increased hybridisation temperature (49.5°C) in combination with a reduced amplicon volume (1µl) to avoid cross-reactivity. In conclusion, the SPF10 real-time PCR proves to be very sensitive and generates amplicons, which are compatible with the LiPA.


Subject(s)
Capsid Proteins/genetics , Oncogene Proteins, Viral/genetics , Papillomaviridae/classification , Papillomaviridae/isolation & purification , Real-Time Polymerase Chain Reaction , DNA, Viral/analysis , DNA, Viral/genetics , Genotype , Humans , Papillomaviridae/genetics , Papillomavirus Infections/virology
4.
J Clin Microbiol ; 50(12): 4073-7, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23052314

ABSTRACT

To be acceptable for use in cervical cancer screening, a new assay that detects DNA of high-risk human papillomavirus (hrHPV) types must demonstrate high reproducibility and performance not inferior to that of a clinically validated HPV test. In the present study, a real-time quantitative PCR (qPCR) assay targeting the E6 and E7 genes of hrHPV was compared with Hybrid Capture 2 (hc2) in a Belgian cervical cancer screening setting. In women >30 years old, the sensitivity and specificity for intraepithelial neoplasias of grade 2 or worse (93 cases of cervical intraepithelial neoplasias of grade 2 or worse (CIN2+) and 1,207 cases of no CIN or CIN1) were 93.6% and 95.6%, respectively, and those of hc2 were 83.9% and 94.5%, respectively {relative sensitivity of qPCR/hc2 = 1.12 [95% confidence interval (CI), 1.01 to 1.23]; relative specificity = 1.01 [95% CI, 0.99 to 1.03]}. A score test showed that the sensitivity (P < 0.0001) and specificity (P < 0.0001) of the qPCR assay were not inferior to those of hc2 at the required thresholds of 90% and 98%, respectively. The overall agreement of hrHPV positivity between the two runs of the qPCR tests was 98.7% (95% CI, 97.5 to 99.4%), with a kappa value of 0.96 (95% CI, 0.83 to 1.00). The qPCR assay used in this study can be considered a reliable HPV assay that fulfills the clinical validation criteria defined for use in cervical cancer screening.


Subject(s)
Early Detection of Cancer/methods , Papillomaviridae/isolation & purification , Papillomavirus Infections/diagnosis , Papillomavirus Infections/virology , Real-Time Polymerase Chain Reaction/methods , Uterine Cervical Neoplasms/prevention & control , Uterine Cervical Neoplasms/virology , Adult , Aged , Belgium , Carcinogens , Female , Humans , Middle Aged , Molecular Diagnostic Techniques/methods , Papillomaviridae/genetics , Sensitivity and Specificity , Viral Proteins/genetics , Virology/methods
5.
Vaccine ; 30(46): 6573-7, 2012 Oct 12.
Article in English | MEDLINE | ID: mdl-22939906

ABSTRACT

PURPOSE: The prevalence of penile cancer varies between 1.5 (industrialized countries) and 4.5 per 100,000 men (non-industrialized countries). Predominant histological subtype is squamous cell carcinoma (SCC). Human papillomavirus (HPV) is found in 40-46% of cases: penile cancer is considered to behave as vulvar cancer. Non HPV related risk factors are lack of circumcision, phimosis, chronic inflammation, and smoking. The role of lichen sclerosus (LS) is unclear. Clinical diagnosis is difficult and treatment often mutilating. Preventive measures can be taken since the risk factors are known: the use of the prophylactic HPV vaccines may contribute. We measured the prevalence of HPV and LS in penile cancer in Belgium. MATERIALS AND METHODS: We found 76 samples of penile lesions in the archives of the departments of Histology of four university hospitals in Belgium. Real-time PCR of type-specific HPV DNA was performed targeting 18 HPV types. PRINCIPAL RESULTS: Patients with penile intraepithelial neoplasia (PeIN) were 56.1 years of age: patients with invasive penile cancer (IPC) 68.5 (p=0.009). Fifty-five samples (55/76) were adequate for HPV targeting. Overall HPV DNA was 70.9%: 89.5% in samples of PeIN (n=19) and 61.1% in samples of IPC (n=36). Invasive penile cancer samples were less likely to be HPV infected (p=0.028). HPV 16 was most prevalent: 48.3%: 20% PeIN, and 28.3% IPC. HPV DNA of the types, included in the prophylactic vaccines, was found in 33% of PeIN and 31.7% of IPC samples. Thrice, low risk HPV (lrHPV) types 6 (1 IPC) and 11 (1 PeIN, 1 IPC) were solely present. There was no difference in the presence of LS between HPV positive and HPV negative samples (p=0.944). CONCLUSIONS: Prevalence of HPV DNA in penile lesions in Belgium is high. However, the prophylactic vaccines may contribute to primary prevention of only a subset of cases. The role of LS remains unclear.


Subject(s)
Lichen Sclerosus et Atrophicus/complications , Lichen Sclerosus et Atrophicus/epidemiology , Papillomavirus Infections/complications , Papillomavirus Infections/epidemiology , Penile Neoplasms/epidemiology , Penile Neoplasms/etiology , Adult , Aged , Aged, 80 and over , Belgium/epidemiology , DNA, Viral/genetics , DNA, Viral/isolation & purification , Genotype , Humans , Lichen Sclerosus et Atrophicus/virology , Male , Middle Aged , Papillomaviridae/classification , Papillomaviridae/genetics , Papillomaviridae/isolation & purification , Papillomavirus Infections/virology , Penile Neoplasms/virology , Prevalence , Real-Time Polymerase Chain Reaction , Young Adult
6.
J Virol Methods ; 2012 May 22.
Article in English | MEDLINE | ID: mdl-22626567

ABSTRACT

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.

7.
Perfusion ; 24(4): 239-42, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19843622

ABSTRACT

In open heart surgery in neonates and small children, the cardiopulmonary bypass circuit surface and the priming volume are relatively large in relation to patient size and blood volume. Therefore, the use of allogeneic blood is inevitable to maintain the optimal hematocrit level during bypass. To avoid the deleterious effects of blood transfusion, as well as to reduce the contact surface of blood with artificial materials, we stepwise reduced the bypass circuit size. Use of the commercially available minimized elements and an adjusted set-up of the system allowed us to reduce usage of allogeneic blood in the prime and during the bypass. However, other supplemental measures are needed to obtain asanguineous cardiopulmonary bypass for neonatal and infant patients.


Subject(s)
Blood Transfusion/statistics & numerical data , Cardiopulmonary Bypass/instrumentation , Heart Defects, Congenital/surgery , Miniaturization , Oxygenators, Membrane , Cardiopulmonary Bypass/adverse effects , Humans , Infant , Medical Audit , Retrospective Studies , Transfusion Reaction
8.
J Clin Pathol ; 61(5): 637-41, 2008 May.
Article in English | MEDLINE | ID: mdl-18227140

ABSTRACT

AIMS: Cervical cytology biobanking is a feasible concept in cervical pathology and could be an indispensable tool for fundamental and applied molecular biological research. PCR is a powerful molecular technique that can be performed on a variety of cervical sample types including Pap-stained cervical smears. However, since the quality of DNA from such specimens is inferior to that from fresh tissue, the correct processing methods are required. This study evaluates three commercial isolation methods and one digestion procedure for their ability to obtain DNA suitable for PCR from fixed and stained Pap smears. METHODS: The High Pure PCR Template Preparation kit, the NucliSENS easyMAG system, the QIAamp DNA Mini Kit and crude proteinase K digestion were used to obtain DNA for subsequent PCR applications. Amplification of beta-globin was performed to verify the presence and integrity of target DNA. The influence of PCR inhibitors and extent of DNA fragmentation were analysed. RESULTS: All commercial DNA isolation techniques provided DNA suitable for PCR amplification, and DNA isolated from 10-year-old archival smears yielded amplicons up to 400 base pairs. Conversely, crude proteinase K digestion limited the amplicon size to 300 bp and did not consistently yield amplifiable digests, as these were contaminated with PCR-inhibiting factors and debris. CONCLUSION: The study indicates that commercial DNA isolation techniques are suitable for PCR amplification of DNA isolated from archival smears, yielding amplicons up to 400 base pairs. Proteinase K digestion is not suitable to obtain amplifiable DNA from fixed and stained Pap-stained smears.


Subject(s)
Biological Specimen Banks , DNA/isolation & purification , Papanicolaou Test , Vaginal Smears , Female , Humans , Polymerase Chain Reaction/methods , Reagent Kits, Diagnostic , Specimen Handling/methods , Staining and Labeling
9.
10.
J Cell Mol Med ; 11(4): 881-91, 2007.
Article in English | MEDLINE | ID: mdl-17760847

ABSTRACT

The causal relationship between persistent infection with high-risk HPV and cervical cancer has resulted in the development of HPV DNA detection systems. The widely used MY09/11 consensus PCR targets a 450bp conserved sequence in the HPV L1 gene, and can therefore amplify a broad spectrum of HPV types. However, limitations of these consensus primers are evident, particularly in regard to the variability in detection sensitivity among different HPV types. This study compared MY09/11 PCR with type-specific PCRs in the detection of oncogenic HPV types. The study population comprised 15, 774 patients. Consensus PCR failed to detect 522 (10.9%) HPV infections indicated by type-specific PCRs. A significant correlation between failure of consensus PCR and HPV type was found. HPV types 51, 68 and 45 were missed most frequently. The clinical relevance of the HPV infections missed by MY09/11 PCR was reflected in the fraction of cases with cytological abnormalities and in follow-up, showing 104 (25.4%) CIN2+ cases. The MY09/11 false negativity could be the result of poor sensitivity, mismatch of MY09/11 primers or disruption of L1 target by HPV integration or DNA degradation. Furthermore, MY09/11 PCR lacked specificity for oncogenic HPVs. Diagnostic accuracy of the PCR systems, in terms of sensitivity (MY09/11 PCR: 87.9%; type-specific PCRs: 98.3%) and specificity (MY09/11 PCR: 38.7%; type-specific PCRs: 76.14%), and predictive values for histologically confirmed CIN2+, suggest that type-specific PCRs could be used in a clinical setting as a reliable screening tool.


Subject(s)
Alphapapillomavirus/genetics , Alphapapillomavirus/isolation & purification , Consensus Sequence , DNA, Viral/analysis , DNA, Viral/genetics , Oncogenic Viruses/genetics , Polymerase Chain Reaction/methods , Base Pair Mismatch , Female , Follow-Up Studies , Humans , Oncogenic Viruses/isolation & purification , Predictive Value of Tests , Sensitivity and Specificity , Species Specificity
11.
J Clin Pathol ; 60(8): 896-901, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17660333

ABSTRACT

BACKGROUND: Human papillomavirus (HPV) plays a critical role in the carcinogenesis of squamous cervical carcinoma. Integration of viral DNA into the host genome is a major contributing factor to malignant transformation. Viral load may influence integration. AIMS: To compare HPV status (type, viral load, integration status) between normal samples, carcinoma in situ and invasive carcinoma in order to elucidate the role of HPV in progression to invasive lesions. METHODS: The study population comprised 10 biopsy samples from each diagnostic group. Laminin-5 immunohistochemistry was performed to distinguish invasive carcinoma from non-invasive high-grade lesions. Real-time PCR was used to detect specific HPV types, viral load and integrated HPV, with quantification of viral E2 and E6 genes. RESULTS: Invasive carcinomas contained a higher number of laminin-5 immunoreactive cells as compared to non-invasive lesions. Almost all samples contained HPV, with a higher viral load and copy number of HPV16 integrated in E2 in cases of laminin-5 immunoreactivity and cases of invasive carcinoma. High HPV16 viral load was associated with more integrated copies in E2. CONCLUSIONS: HPV is important in progression from carcinoma in situ to invasive carcinoma. Viral load and HPV integration influence the development of cervical cancer towards invasiveness. Overall HPV status may be more predictive of patient outcome and may influence patient management.


Subject(s)
Carcinoma, Squamous Cell/immunology , Cell Adhesion Molecules/immunology , Papillomavirus Infections/genetics , Uterine Cervical Neoplasms/immunology , Carcinoma, Squamous Cell/complications , Carcinoma, Squamous Cell/virology , DNA, Viral/genetics , Disease Progression , Female , Genes, Viral , HeLa Cells , Human papillomavirus 6/genetics , Humans , Immunohistochemistry/methods , Neoplasm Invasiveness , Papillomaviridae/genetics , Papillomavirus Infections/complications , Papillomavirus Infections/immunology , Uterine Cervical Neoplasms/complications , Uterine Cervical Neoplasms/virology , Viral Load , Uterine Cervical Dysplasia/complications , Uterine Cervical Dysplasia/immunology , Uterine Cervical Dysplasia/virology , Kalinin
13.
Cytopathology ; 17(6): 374-81, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17168921

ABSTRACT

OBJECTIVE: Liquid-based cytology (LBC) for cervical screening is becoming increasingly used. Together with SurePath LBC, various collecting devices can be utilized, among which the Cervex-Brush is the most widely used. The new Rovers Cervex-Brush Combi combines the advantages of the Cervex-Brush with the EndoCervex-Brush increasing sampling of the endocervical canal. The objective of this study was to analyse and to compare the Cervex-Brush Combi with the Cervex-Brush for the collection of squamous and endocervical cells, human papillomavirus (HPV) typing/quantification and disease detection in SurePath LBC. METHODS: Using either the Cervex-Brush or the Cervex-Brush Combi 100 consecutive SurePath LBC samples were collected using each brush type. All 200 slides were read by the FocalPoint and screened by guided screening using slide wizards. The viral load of HPV type 16 E7, 18 E7, 31 E6, 33 L1, 33 E6, 35 E4, 39 E7, 45 E7, 51 E6, 52 L1, 52 E7, 53 E6, 56 E7, 58 L1, 58 E6, 59 E7, 66 E6 and 68 E7 was determined using a TaqMan-based real-time quantitative PCR analysis. RESULTS: The mean number of sampled squamous cells did not differ between the two brush types (54 963 versus 54 595 cells). The use of the Cervex-Brush Combi, however, resulted in a two- to threefold increase in the number of sampled endocervical cells (P < 0.00001). Using the Cervex-Brush Combi slightly more lesions were detected (three versus two low-grade squamous intraepithelial lesions), and resulted in the detection of more atypical squamous cells of undetermined significance (six versus three). In the Cervex-Brush group, 60% (3/5) of abnormal smears were positive for oncogenic HPV types, whereas 66.7% (6/9) of abnormal smears in the Cervex-Brush Combi group tested positive. The median HPV viral load for samples taken with the Cervex-Brush Combi was 0.1825 copies/cell and was significantly higher than in samples taken with the Cervex-Brush (0.0042 copies/cell) (P = 0.02). CONCLUSION: Sampling with the Cervex-Brush Combi resulted in the collection of the same amount of squamous cells, but in a two to threefold harvest of endocervical cells. This led to the detection of a higher viral load for oncogenic HPV and an increase in the number of detected abnormal smears.


Subject(s)
Papillomaviridae/isolation & purification , Papillomavirus Infections/virology , Uterine Cervical Diseases/virology , Uterine Cervical Neoplasms/virology , Vaginal Smears/methods , Cohort Studies , Female , Humans , Mass Screening/methods , Papillomaviridae/genetics , Papillomavirus Infections/pathology , Polymerase Chain Reaction/methods , Prospective Studies , Uterine Cervical Diseases/pathology , Uterine Cervical Neoplasms/pathology , Vaginal Smears/standards , Viral Load
14.
Best Pract Res Clin Obstet Gynaecol ; 19(4): 469-83, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16150388

ABSTRACT

Human papillomavirus (HPV) infection is the most common sexually transmitted disease, with more than 80% of the population infected at some time in their life. In rare cases, this infection may lead to cervical cancer. Virtually all squamous cell carcinomas and the overwhelming majority of adenocarcinomas of the cervix are HPV positive. HPV integration in the genome will lead to inactivation of the p53 pathway and the Rb pathway. Integration is essential for the onset of cervical carcinogenesis, but is probably not sufficient for progression to invasive cervical cancers. It is likely that several cofactors, such as environmental, viral and host-related factors, are necessary for the development of cervical cancer. There are several similarities and differences between the two major histological types. This article will address the role of HPV in cervical carcinogenesis as well as the molecular biology involved in the process.


Subject(s)
Adenocarcinoma/virology , Carcinoma, Squamous Cell/virology , Papillomavirus Infections/complications , Sexually Transmitted Diseases, Viral/complications , Uterine Cervical Neoplasms/virology , Adenocarcinoma/blood supply , Apoptosis/physiology , Carcinoma, Squamous Cell/blood supply , Diet/adverse effects , Environmental Exposure/adverse effects , Female , Humans , Life Style , Neovascularization, Pathologic/complications , Papillomaviridae/pathogenicity , Retinoblastoma Protein/metabolism , Risk Factors , Sexual Behavior , Tumor Suppressor Protein p53/metabolism , Uterine Cervical Neoplasms/blood supply
15.
Int J Gynecol Cancer ; 14(5): 751-61, 2004.
Article in English | MEDLINE | ID: mdl-15361181

ABSTRACT

Persistent infection with one of the oncogenic human papillomavirus (HPV) types is a necessity for the development of cervical cancer. By HPV vaccination, cervical cancer could become a very rare disease. Two types of HPV vaccines can be distinguished: (i) therapeutic vaccines which induce cellular immunity targeted against epithelial cells infected with HPV and (ii) prophylactic vaccines inducing virus-neutralizing antibodies protecting against new but not against established infections. At present, several vaccines have been developed and tested in clinical trials. The vaccines are generally well tolerated and highly immunogenic. The current clinical data indicate that prophylactic vaccines are very effective against new persistent infections and the development of cervical intraepithelial lesions. The protection is type specific. However, the follow-up of the vaccination trials is still short. The effect of HPV vaccines on future cancer incidence will only be known after decades of follow-up. This article will address the status of recently terminated phase II and currently running phase III trials with prophylactic HPV vaccines.


Subject(s)
Papillomaviridae/pathogenicity , Papillomavirus Infections/complications , Papillomavirus Infections/prevention & control , Papillomavirus Vaccines , Uterine Cervical Neoplasms/prevention & control , Uterine Cervical Neoplasms/virology , Viral Vaccines , Antibodies, Viral/immunology , Antibody Formation , Clinical Trials as Topic , Female , Humans , Papillomaviridae/immunology , Uterine Cervical Neoplasms/immunology , Uterine Cervical Dysplasia/immunology , Uterine Cervical Dysplasia/prevention & control , Uterine Cervical Dysplasia/virology
16.
Eur J Gynaecol Oncol ; 25(1): 40-4, 2004.
Article in English | MEDLINE | ID: mdl-15053060

ABSTRACT

Small cell cancers of the cervix are very rare and aggressive tumours. It is difficult to manage these tumours. They are often diagnosed in an advanced stage and their prognosis is generally poor. There are no clinical trials, due to their rarity, that would suggest optimal treatment. The present report describes a patient with a neuroendocrine small cell cancer of the cervix Stage IB2 with a positive lymph node. The treatment consisted of radical hysterectomy and node dissection, adjuvant chemotherapy, chemoradiation and brachytherapy. Currently, after 52 months, the patient is well and free of disease. Since 1996, there has been a classification for neuroendocrine tumours (NETs) of the cervix in four categories (large cell, small cell, typical carcinoid and atypical carcinoid). The aggressive behaviour of neuroendocrine small cell cancer is demonstrated by the high percentage of early lymphatic node and vessel invasion (68 and 90%). Almost half of the patients with Stage I and II will recur with an estimated 5-year survival from 14% to a maximum of 55%. Multimodal therapy for these tumours appears to give good response but often implies severe side-effects.


Subject(s)
Carcinoma, Neuroendocrine/diagnosis , Carcinoma, Neuroendocrine/therapy , Uterine Cervical Neoplasms/diagnosis , Uterine Cervical Neoplasms/therapy , Adult , Carcinoma, Neuroendocrine/pathology , Combined Modality Therapy , Decision Trees , Diagnosis, Differential , Female , Humans , Lymphatic Metastasis , Neoplasm Staging , Uterine Cervical Neoplasms/pathology
17.
Acta Clin Belg ; 58(4): 211-9, 2003.
Article in English | MEDLINE | ID: mdl-14635528

ABSTRACT

The causal relationship between genital human papillomavirus (HPV) infection and cervical dysplasia/carcinoma has been recognised for some time. The aim of this study was to document the occurrence and distribution of HPV infection in the five provinces of the Flemish region in Belgium and to correlate the HPV DNA test results with the cytological results on simultaneously performed thin layer preparations of cervical cells. Out of a total screened group of 105107 samples, 1978 samples with cytological abnormalities were tested for HPV DNA using the MY09/MY11 consensus PCR. The mean age of the whole group was 36.9 years. The LSIL group, with a mean age of 33.6 years, was significantly younger than the other groups. There was no significant difference in HPV prevalence among the provinces. In four out of five provinces the HPV prevalence reached 100% in high-grade lesions. There is a significant increase in predominance of high-risk HPV types, with increasing abnormal cytology (17.9% WNL < 51.1% ASCUS < 83.8% LSIL < 97.2% HSIL). Three peaks of HPV DNA positivity were observed, a first at 22 yrs (82%), a second at 47 yrs (60%) and a third in women older than 65 yrs (52%). These results shed more light on HPV prevalence in Flanders and show that the MY09/MY11 consensus primer based detection system is very suitable for the detection of HPV infections in Flanders.


Subject(s)
Papillomaviridae/isolation & purification , Papillomavirus Infections/epidemiology , Precancerous Conditions/epidemiology , Uterine Cervical Dysplasia/epidemiology , Uterine Cervical Neoplasms/epidemiology , Adult , Age Distribution , Aged , Analysis of Variance , Belgium/epidemiology , Biopsy, Needle , DNA, Viral/analysis , Female , Humans , Mass Screening , Middle Aged , Papillomavirus Infections/pathology , Polymerase Chain Reaction , Precancerous Conditions/pathology , Prevalence , Probability , Uterine Cervical Neoplasms/pathology , Uterine Cervical Dysplasia/pathology
19.
J Clin Pathol ; 56(9): 681-6, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12944552

ABSTRACT

AIMS: To test the ability of Ki-67 to detect cytological lesions in a screening setting and its use as a surrogate marker of human papillomavirus (HPV) infection. METHODS: A study of liquid based cytology, HPV DNA testing by MY09/MY11 consensus polymerase chain reaction (PCR), type specific PCRs, and Ki-67 immunocytochemistry on a randomly selected series of 147 patients. RESULTS: Comparison of the number of Ki-67 immunoreactive cells/1000 cells in the different cytological groups showed that the HSIL group yielded a significantly higher mean count than did the other groups. The number of Ki-67 immunoreactive cells/1000 cells was significantly higher in HPV-16 positive samples than in samples containing infections with other high risk types. Receiver operating characteristic curves indicated a test accuracy (area under curve) of 0.68, 0.72, and 0.86 for atypical squamous cells of undetermined significance (ASCUS), low grade squamous intraepithelial lesions (LSIL), and high grade squamous intraepithelial lesions (HSIL), respectively. Thresholds for 95% sensitivity were 0.07, 0.08, and 0.15 Ki-67 immunopositive cells/1000 cells for ASCUS, LSIL and HSIL, respectively. The threshold for 95% specificity was 1.9 Ki-67 immunopositive cells/1000 cells. CONCLUSIONS: Ki-67 immunocytochemistry can be applied to liquid based cytology. The accuracy and diagnostic indices of the test are good when compared with those of other techniques. As part of a panel of screening procedures, it could be used as an adjunct to liquid based cytology to identify HSIL, and as a surrogate marker of HPV-16 infection.


Subject(s)
Ki-67 Antigen/analysis , Papillomavirus Infections/diagnosis , Tumor Virus Infections/diagnosis , Uterine Cervical Diseases/diagnosis , Vaginal Smears , Biomarkers/analysis , DNA, Viral/analysis , Female , Humans , Immunohistochemistry/methods , Papillomaviridae/genetics , Polymerase Chain Reaction/methods , ROC Curve , Sensitivity and Specificity , Uterine Cervical Diseases/virology
20.
Br J Cancer ; 88(4): 560-6, 2003 Feb 24.
Article in English | MEDLINE | ID: mdl-12592370

ABSTRACT

The objective of this study was to document the occurrence and to correlate the prevalence of different human papillomavirus (HPV) types with the cytological results on simultaneously performed thin-layer preparations in a large population of Flemish women. During 1 year, 69 290 thin-layer preparations were interpreted using the Bethesda classification system. Using an algorithm for HPV testing based on consensus primers and type-specific PCRs in combination with liquid-based cytology, we determined the occurrence and distribution of 14 different oncogenic HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). Reflex HPV testing was performed on cytologically abnormal samples and on an age matched randomly selected control group with normal cervical cytology (n=1351). Correlation between cytology, age and prevalence for the 14 different high-risk HPV types is given. There is a significant increase in predominance of high-risk HPV types, with increasing abnormal cytology. Coinfection with multiple HPV types also increased with cytological abnormalities, and was highest in HSIL (16.7%). In Flanders, HSIL was most often associated with HPV types 16, 33, 35, 31, 18 and 51. Using thin-layer liquid-based cytology and PCR to detect HPV, it is feasible to screen large numbers of women.


Subject(s)
Cytological Techniques/methods , DNA, Viral/analysis , Papillomaviridae/classification , Papillomaviridae/genetics , Papillomavirus Infections/diagnosis , Papillomavirus Infections/virology , Polymerase Chain Reaction/methods , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Belgium/epidemiology , Cervix Uteri/pathology , Cervix Uteri/virology , DNA, Viral/genetics , Female , Humans , Mass Screening/methods , Middle Aged , Papillomavirus Infections/epidemiology , Papillomavirus Infections/pathology , Prevalence , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...